MSC-NTF

MSC-NTF (NurOwn) is an investigational cell therapy consisting of autologous, bone marrow-derived mesenchymal stem cells (MSCs) that are expanded and differentiated ex vivo to secrete high levels of neurotrophic factors (NTFs). The process involves collecting a patient's own bone marrow, isolating and expanding the MSCs, and then inducing them under patented conditions to produce NTFs. These modified cells are then administered intrathecally (into the spinal fluid), where they are intended to deliver neuroprotective and immunomodulatory effects directly at sites of neuronal damage. The primary mechanism is believed to be the secretion of multiple NTFs that support neuron survival, modulate immune responses in the central nervous system, promote remyelination, and potentially slow or stabilize disease progression. Developed by BrainStorm Cell Therapeutics, this therapy is primarily being investigated for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS)[1][2][4][5].

Brand names

NurOwn

Other names

autologous mesenchymal stem cells secreting neurotrophic factorsautologous MSC-NTF cellsmesenchymal stromal cells secreting neurotrophic factors